# 177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer

> **NCT05613738** · NA · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 9 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01
- **DRUG:** 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01
- **DRUG:** 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01

## Key facts

- **NCT ID:** NCT05613738
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-23
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-11-15
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2024-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05613738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05613738, "177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05613738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*